Relay Therapeutics Inc ((RLAY)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Relay Therapeutics Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3 Open-Label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment With a CDK4/6 Inhibitor.’ The study aims to evaluate the efficacy and safety of RLY-2608 in combination with fulvestrant compared to capivasertib with fulvestrant in treating HR+/HER2- breast cancer with PIK3CA mutation.
The study tests two drug combinations: RLY-2608 + fulvestrant and capivasertib + fulvestrant. RLY-2608 is administered orally, while fulvestrant is given intramuscularly, targeting advanced breast cancer treatment.
This interventional study is randomized with a parallel assignment model and no masking, focusing primarily on treatment efficacy. Patients are allocated to either the experimental or active comparator group to assess outcomes.
The study is currently recruiting, with an estimated start date of July 31, 2025. The primary completion and estimated study completion dates are yet to be announced. The last update was submitted on July 29, 2025.
Relay Therapeutics’ study could significantly influence its stock performance by demonstrating effective treatment options, potentially increasing investor confidence. The study’s outcome may also impact the competitive landscape in the breast cancer treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.